Core Viewpoint - The stock of TEBIO has shown fluctuations with a recent increase of 2.03%, reflecting a total market capitalization of 30.406 billion yuan and a trading volume of 116 million yuan as of November 3 [1]. Financial Performance - For the period from January to September 2025, TEBIO reported a revenue of 2.48 billion yuan, representing a year-on-year growth of 26.85%. The net profit attributable to shareholders was 666 million yuan, showing a year-on-year increase of 20.21% [2]. - Cumulatively, TEBIO has distributed a total of 577 million yuan in dividends since its A-share listing, with 506 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, TEBIO had 8,608 shareholders, an increase of 2% from the previous period. The average number of circulating shares per shareholder decreased by 1.96% to 47,258 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by E Fund's SSE STAR 50 ETF and Huaxia's SSE STAR 50 Component ETF, with reductions of 856,700 shares and 3,216,200 shares respectively [3]. Stock Performance - TEBIO's stock price has increased by 2.39% year-to-date, with a 4.92% rise over the last five trading days. However, it has experienced a decline of 9.19% over the past 20 days and 17.90% over the last 60 days [1].

Core Viewpoint - The stock of TEBIO has shown a slight increase of 2.03% on October 29, with a current price of 72.45 CNY per share, despite a year-to-date decline of 0.41% and a more significant drop of 6.29% over the past five trading days [1] Financial Performance - For the period from January to September 2025, TEBIO achieved a revenue of 2.48 billion CNY, representing a year-on-year growth of 26.85%. The net profit attributable to shareholders was 666 million CNY, reflecting a growth of 20.21% compared to the previous year [2] Shareholder Information - As of September 30, 2025, TEBIO had 8,608 shareholders, an increase of 2% from the previous period. The average number of circulating shares per shareholder decreased by 1.96% to 47,258 shares [2] Dividend Distribution - TEBIO has distributed a total of 577 million CNY in dividends since its A-share listing, with 506 million CNY distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the seventh-largest circulating shareholder is E Fund's SSE STAR 50 ETF, holding 5.88 million shares, a decrease of 856,700 shares from the previous period. The eighth-largest shareholder is Huaxia's SSE STAR 50 Component ETF, holding 5.73 million shares, down by 3.22 million shares [3]

Core Viewpoint - The stock of TEBIO has experienced a decline, with a current price of 71.16 CNY per share, reflecting a year-to-date drop of 2.19% and a significant decrease over the past five trading days of 8.36% [1] Financial Performance - For the period from January to September 2025, TEBIO reported a revenue of 2.48 billion CNY, representing a year-on-year growth of 26.85%. The net profit attributable to shareholders was 666 million CNY, showing a year-on-year increase of 20.21% [2] Shareholder Information - As of September 30, 2025, TEBIO had 8,608 shareholders, an increase of 2% from the previous period. The average number of circulating shares per shareholder decreased by 1.96% to 47,258 shares [2] Dividend Distribution - TEBIO has distributed a total of 577 million CNY in dividends since its A-share listing, with 506 million CNY distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the seventh-largest circulating shareholder is E Fund's SSE STAR 50 ETF, holding 5.88 million shares, a decrease of 856,700 shares from the previous period. The eighth-largest shareholder is Huaxia's SSE STAR 50 Component ETF, holding 5.73 million shares, down by 3.22 million shares [3]

Core Viewpoint - The stock price of TEBIO has been declining for four consecutive days, with a total drop of 7.44% during this period, indicating potential concerns among investors [1]. Company Overview - TEBIO, officially known as Xiamen TEBIO Engineering Co., Ltd., was established on August 7, 1996, and went public on January 17, 2020. The company specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs [1]. - The main revenue composition of TEBIO includes antiviral drugs (86.85%), blood/cancer drugs (12.87%), and other supplementary products (0.27%) [1]. Fund Holdings - Huatai-PB Fund has a significant holding in TEBIO, with its Huatai-PB Quantitative Chuangying Mixed A Fund (010303) holding 15,400 shares, unchanged from the previous period, accounting for 1.34% of the fund's net value [2]. - The fund has experienced a floating loss of approximately 18,500 yuan today, with a total floating loss of 96,100 yuan during the four-day decline [2]. - The Huatai-PB Quantitative Chuangying Mixed A Fund was established on November 12, 2020, with a current scale of 58.35 million yuan and has achieved a year-to-date return of 43.46% [2].

Core Viewpoint - The stock of TEBIO experienced a decline of 2.06% on October 16, 2023, with a trading volume of 1.40 billion yuan and a market capitalization of 31.974 billion yuan [1] Financial Performance - For the first half of 2025, TEBIO reported a revenue of 1.511 billion yuan, representing a year-on-year growth of 26.96%, and a net profit attributable to shareholders of 428 million yuan, which is a 40.60% increase compared to the previous year [2] Shareholder and Market Activity - As of June 30, 2025, TEBIO had 8,439 shareholders, an increase of 13.00% from the previous period, with an average of 48,204 circulating shares per shareholder, down by 11.51% [2] - The stock's performance shows an 8.04% increase year-to-date, but a decline of 3.44% over the last five trading days and 3.99% over the last twenty days [1] Dividend Distribution - TEBIO has distributed a total of 577 million yuan in dividends since its A-share listing, with 506 million yuan distributed over the last three years [3] Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included the Huaxia SSE STAR 50 ETF, which increased its holdings by 837,500 shares, and the E Fund SSE STAR 50 ETF, which added 189,900 shares [3]

Core Viewpoint - The stock of TEBIO experienced a decline of 2.00% on October 14, with a current price of 82.21 CNY per share and a market capitalization of 33.443 billion CNY. The company has seen a year-to-date stock price increase of 13.00% but has faced a slight decline in the recent trading periods [1]. Financial Performance - For the first half of 2025, TEBIO reported a revenue of 1.511 billion CNY, representing a year-on-year growth of 26.96%. The net profit attributable to shareholders was 428 million CNY, showing a year-on-year increase of 40.60% [2]. - Since its A-share listing, TEBIO has distributed a total of 577 million CNY in dividends, with 506 million CNY distributed over the past three years [3]. Shareholder and Market Activity - As of June 30, 2025, TEBIO had 8,439 shareholders, an increase of 13.00% from the previous period. The average number of circulating shares per shareholder decreased by 11.51% to 48,204 shares [2]. - The major shareholders include ETFs such as 华夏上证科创板50成份ETF and 易方达上证科创板50ETF, which have increased their holdings [3]. Company Overview - TEBIO, established on August 7, 1996, and listed on January 17, 2020, is based in Xiamen, Fujian Province. The company specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs, with a revenue composition of 86.85% from antiviral drugs and 12.87% from blood/cancer drugs [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in the biopharmaceuticals category [1].

Core Viewpoint - The stock of TEBIO has shown a positive trend with a year-to-date increase of 15.02% and a recent rise of 5.63% over the last five trading days, indicating strong market interest and performance [1]. Financial Performance - For the first half of 2025, TEBIO reported a revenue of 1.511 billion yuan, representing a year-on-year growth of 26.96% [2]. - The net profit attributable to shareholders for the same period was 428 million yuan, reflecting a year-on-year increase of 40.60% [2]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 8,439, up by 13 compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 11.51% to 48,204 shares [2]. Dividend Distribution - TEBIO has distributed a total of 577 million yuan in dividends since its A-share listing, with 506 million yuan distributed over the last three years [3]. Institutional Holdings - As of June 30, 2025, major institutional shareholders include Huaxia SSE STAR 50 ETF and E Fund SSE STAR 50 ETF, with both increasing their holdings [3].

Company Overview - Teabo Bioengineering Co., Ltd. is located in Xiamen, Fujian Province, established on August 7, 1996, and listed on January 17, 2020. The company specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs [1][2] - The main business revenue composition includes antiviral drugs (86.85%), blood/cancer drugs (12.87%), and other (supplement) (0.27%) [1] Financial Performance - For the first half of 2025, Teabo Bio achieved operating revenue of 1.511 billion yuan, a year-on-year increase of 26.96%, and a net profit attributable to shareholders of 428 million yuan, a year-on-year increase of 40.60% [2] - Since its A-share listing, Teabo Bio has distributed a total of 577 million yuan in dividends, with 506 million yuan distributed over the past three years [2] Stock Performance - As of September 25, Teabo Bio's stock price increased by 2.08%, reaching 83.08 yuan per share, with a total market capitalization of 33.797 billion yuan [1] - Year-to-date, the stock price has risen by 14.20%, with a 4.46% increase over the last five trading days and a 14.94% increase over the last 60 days [1] Shareholder Information - As of June 30, the number of shareholders for Teabo Bio was 8,439, an increase of 13.00% from the previous period, while the average circulating shares per person decreased by 11.51% to 48,204 shares [2] - Among the top ten circulating shareholders, Huaxia SSE Sci-Tech Innovation 50 ETF and E Fund SSE Sci-Tech Innovation 50 ETF increased their holdings [2]